SCHEMBL6285062

SCHEMBL6285062

CC(=NNC(=N)N)c1cn(S(=O)(=O)c2ccccc2)c2ccc(Cl)cc12

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
PLK1 P53350 1/20 0.43
HTR6 P50406 8/20 0.43
KDM1A O60341 5/20 0.38
AKR1C3 P42330 1/20 0.37
AKR1C1 Q04828 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
TNF P01375 1/20 0.37
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 1/20 0.36
BRD4 O60885 1/20 0.36
CYP2C9 P11712 1/20 0.36
BRD2 P25440 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6285056 1.00 LMNA (0.46) LMNASMN1; SMN2MEN1KMT2APLK1
SCHEMBL6287718 0.90 HTR6 (0.43) LMNASMN1; SMN2HTR6TNF
SCHEMBL6287714 0.90 HTR6 (0.43) LMNASMN1; SMN2HTR6TNF
SCHEMBL6284975 0.89 HTR6 (0.44) HTR6ALDH1A1CYP3A4CYP2D6
SCHEMBL6284982 0.89 HTR6 (0.44) HTR6ALDH1A1CYP3A4CYP2D6
SCHEMBL6286980 0.88 HTR6 (0.47) LMNASMN1; SMN2MEN1KMT2APLK1
SCHEMBL6285182 0.88 LMNA (0.46) LMNASMN1; SMN2MEN1KMT2APLK1
SCHEMBL6285187 0.88 LMNA (0.46) LMNASMN1; SMN2MEN1KMT2APLK1
SCHEMBL6286978 0.88 HTR6 (0.47) LMNASMN1; SMN2MEN1KMT2APLK1
SCHEMBL6286906 0.87 LMNA (0.60) LMNASMN1; SMN2MEN1KMT2APLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US claimed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US claimed
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US disclosed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2A LMNA 4212/4885SMN1; SMN2 3120/4885MEN1 3107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.